Dolby Laboratories filings document the regulatory disclosures of a technology licensing and cinema-products company whose Class A common stock trades on the New York Stock Exchange under DLB. Recent Form 8-K reports furnish quarterly and annual financial results, dividend declarations for Class A and Class B common stock, and related exhibits.
The company’s proxy and governance filings cover director elections, advisory executive-compensation votes, auditor ratification and executive incentive compensation arrangements. The filings also describe Dolby’s dual-class voting structure, with Class A and Class B common stock voting together on most stockholder matters except where law requires otherwise.
Dolby Laboratories (DLB) filed a Form 4 for CFO Robert Park. The filing reports 3,552 shares of Class A common stock withheld at $69.11 to cover taxes upon RSU vesting, a transaction exempt under Rule 16b‑3.
Following the withholding, Park beneficially owns 66,085 shares, including 38,186 shares underlying RSUs that remain subject to forfeiture until they vest. Holdings also include 350 shares acquired under the Employee Stock Purchase Plan on May 15, 2025.
Dolby Laboratories (DLB) reported insider activity by President & CEO and Director Kevin Yeaman. On 10/14/2025, he exercised an employee stock option for 25,000 Class A shares at $45.5 per share (code M), then sold 11,214 shares at a weighted average price of $68.5057 and 13,786 shares at a weighted average price of $69.173 (both code S), all held indirectly by a family trust. Following the reported transactions, 114,725 shares were beneficially owned indirectly by the trust. Holdings also include 127,735 RSUs that are subject to vesting.
Kevin J. Yeaman, President and CEO and a director of Dolby Laboratories (DLB), reported option exercise and related stock sale on 09/16/2025. He exercised an employee stock option with a $45.50 exercise price to acquire 25,000 shares of Class A common stock and immediately reported a sale of 25,000 Class A shares at a weighted average price of $71.6596. After these transactions he beneficially owned 139,725 shares indirectly through the Kevin and Rachel Yeaman Family Trust, including 127,735 Class A shares underlying restricted stock units that remain subject to forfeiture until they vest. The Form 4 was signed by an attorney-in-fact on 09/18/2025.
Form 144 filed for Dolby Laboratories, Inc. (DLB) reports a proposed sale of 25,000 common shares through Morgan Stanley Smith Barney on the NYSE with an aggregate market value of $1,791,487.50 and an approximate sale date of 09/16/2025. The filing states the shares were acquired on 09/16/2025 via stock option exercise from the issuer and paid for in cash. The filer or related parties sold multiple blocks of common stock in the prior three months: 25,000 on 08/12/2025 for $1,807,827.50, 2,491 on 07/16/2025 for $186,825.00, 39,875 on 07/15/2025 for $2,983,287.84, and 25,000 on 06/24/2025 for $1,850,530.00. The form includes the standard representation that the seller is not in possession of undisclosed material adverse information.
Dolby Laboratories director and SVP of Advanced Technology Group, Shriram Revankar, reported an insider sale of 7,000 shares of Class A common stock on 08/22/2025 at a reported price of $74.92 per share. After the sale, Revankar beneficially owned 70,435 shares. The filing discloses that 47,766 of those shares are Class A shares underlying restricted stock units that remain subject to forfeiture until they vest. The Form 4 was signed by an attorney-in-fact on 08/26/2025.
Form 144 filed for Dolby Laboratories (DLB): The filer notifies a proposed sale of 7,000 shares of Common Stock through Morgan Stanley Smith Barney on the NYSE with an approximate aggregate market value of $524,440, and an approximate sale date of 08/22/2025. The shares were acquired as restricted stock: 5,670 shares on 05/16/2023 and 1,330 shares on 12/15/2023. The filing reports no securities sold in the past three months by the selling person. The filer also signs the standard representation that they are not aware of any material nonpublic information about the issuer.
Dolby Laboratories President and CEO Kevin J. Yeaman reported an options exercise-and-sale sequence in Class A common stock. An employee stock option was exercised for 25,000 shares at an exercise price of $45.50 per share, and 25,000 shares were sold at a weighted average price of $72.3131 per share, in multiple trades between $71.63 and $72.59. Following these transactions, an indirect trust position holds 114,725 Class A shares, and additional holdings include 127,735 shares underlying restricted stock units that may be forfeited until vesting, plus a small indirect position of 2.5592 shares reported as held by a son.
Dolby Laboratories (DLB) Form 144 shows a proposed sale of 25,000 common shares through Morgan Stanley Smith Barney on 08/12/2025 with an aggregate market value of $1,807,827.50. The filing lists 95,844,185 shares outstanding, and the securities were acquired the same day by stock option exercise with payment in cash. The notice also records multiple recent sales by Yeaman Family Trust between 06/10/2025 and 07/16/2025 in several tranches. By signing, the seller represents they are not aware of any undisclosed material adverse information; a Rule 10b5-1 plan date is not indicated.